drugset / Trial / NCT00620282

The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus

NCT00620282

Phase 3 Completed 49 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in the United States of America (USA). The purpose of the trial is to assess the effect of liraglutide on forearm blood flow in subjects with type 2 diabetes who are on diet and lifestyle changes or treated with metformin alone.

Timeline

Start
2008-02
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glimepiride Small molecule 4 mg Oral
Subject Liraglutide Peptide 1.8 mg Subcutaneous